Table 3.
Adverse events, serious adverse events, and concurrent treatment.
| Outcome | Number (percentage (%)) |
p value | ||
|---|---|---|---|---|
| Total (n = 52) | TZV group (n = 26) | Placebo group (n = 26) | ||
| Adverse events | 16 (30.8) | 6 (23.1) | 10 (38.5) | 0.2 |
| Nausea and vomiting | 3 (5.8) | 3 (11.5) | 0 | 0.2 |
| Anemia | 3 (5.8) | 0 | 3 (11.5) | 0.2 |
| Diarrhea | 2 (3.8) | 0 | 2 (7.7) | 0.5 |
| Hypokalemia | 2 (3.8) | 0 | 2 (7.7) | 0.5 |
| Sour regurgitation and abdominal discomfort | 1 (1.9) | 1 (3.8) | 0 | 1.0 |
| Hypoalbuminemia | 1 (1.9) | 1 (3.8) | 0 | 1.0 |
| Granulocytopenia | 1 (1.9) | 1 (3.8) | 0 | 1.0 |
| Electrolyte disturbance | 1 (1.9) | 1 (3.8) | 0 | 1.0 |
| Hypoproteinemia | 1 (1.9) | 0 | 1 (3.8) | 1.0 |
| Dizziness | 1 (1.9) | 0 | 1 (3.8) | 1.0 |
| Whole body discomfort and chest tightness | 1 (1.9) | 0 | 1 (3.8) | 1.0 |
| Urinary tract infection | 1 (1.9) | 0 | 1 (3.8) | 1.0 |
| Serious adverse events | 9 (17.3) | 4 (15.4) | 5 (19.2) | 1.0 |
| Death | 1 (1.9) | 0 | 1 (3.9) | 1.0 |
| Admission to ICU | 6 (11.5) | 3 (11.5) | 3 (11.5) | 1.0 |
| Acute hepatic injury | 2 (3.9) | 1 (3.9) | 1 (3.9) | 1.0 |
| Arrhythmia (paroxysmal atrial fibrillation) | 1 (1.9) | 1 (3.9) | 0 | 1.0 |
| Concurrent treatments | 41 (78.9) | 21 (80.8) | 20 (76.9) | 0.7 |
| Antimicrobial drugs | 36 (69.2) | 18 (69.2) | 18 (69.2) | 1.0 |
| Antiviral drugs | 36 (69.2) | 18 (69.2) | 18 (69.2) | 1.0 |
| Interferon | 34 (65.4) | 16 (61.5) | 18 (69.2) | 0.6 |
| Arbidol | 32 (61.5) | 16 (61.5) | 16 (61.5) | 1.0 |
| Ribavirin | 15 (28.9) | 7 (26.9) | 8 (30.8) | 0.8 |
| Lopinavir | 5 (9.6) | 3 (11.5) | 2 (7.7) | 0.6 |
| Antibacterial drugs | 25 (48.1) | 11 (42.3) | 14 (53.8) | 0.4 |
| Hydroxychloroquine | 14 (26.9) | 5 (19.2) | 9 (34.6) | 0.2 |
| Antifungal drugs | 3 (5.8) | 1 (3.8) | 2 (7.7) | 0.6 |
| Chinese medicine therapy | 33 (63.5) | 17 (65.4) | 16 (61.5) | 0.8 |
| Chinese patent medicine | 18 (34.6) | 6 (23.1) | 12 (46.2) | 0.1 |
| Decoction | 10 (19.2) | 6 (23.1) | 4 (15.4) | 0.5 |
| Injection | 14 (26.9) | 8 (30.8) | 6 (23.1) | 0.5 |
| Glucocorticoid therapy | 23 (44.2) | 10 (38.5) | 13 (50.0) | 0.4 |
| Immune regulation therapy | 19 (36.5) | 10 (38.5) | 9 (34.6) | 0.8 |
| Oxygen therapy | 15 (28.8) | 5 (19.2) | 10 (38.5) | 0.2 |
| Antihypertensive drugs | 11 (21.2) | 3 (11.5) | 8 (30.8) | 0.1 |
| Nonsteroidal anti-inflammatory drugs | 7 (13.5) | 2 (7.7) | 5 (19.2) | 0.4 |
| Blood volume expander | 7 (13.5) | 3 (11.5) | 4 (15.4) | 1.0 |
| Antiplatelet drugs | 7 (13.5) | 2 (7.7) | 5 (19.2) | 0.4 |
| Anticoagulants drugs | 5 (9.6) | 2 (7.7) | 3 (11.5) | 1.0 |
| Dilating blood vessels to improve microcirculation | 3 (5.8) | 1 (3.9) | 2 (7.7) | 1.0 |